Low-Level H. pylori: To Treat or Not to Treat – One of the strengths of the GI MAP® is that it detects H. pylori with great sensitivity. However, the ability to quantify just 10 organisms per gram means that H. pylori will be detected at low levels that may not be clinically relevant.
H. pylori is estimated to be present in roughly 50% of the human population but will only cause disease in roughly 15% of those cases. There is evidence that H. pylori can modify the human immune response to confer protection against certain conditions such as asthma, eczema, IBD, diabetes and obesity. Whether H pylori acts as a pathogen or a symbiont will depend on complicated bacterium-host interactions. The art, then, comes with determining which cases of positive H pylori deserve treatment.
Presented by Amy Rolfsen, ND.
Watch this case study to see how Dr. Rolfsen used the GI-MAP on a 36-year-old female patient presenting with a 6-month history of severe upper abdominal pain accompanied by constipation and bloating. The patient also reported fatigue, hair loss and severe premenstrual mood changes, heavy, painful menses with clotting.
Learn more about GI-MAP comprehensive DNA-based stool testing at: https://www.diagnosticsolutionslab.com/tests/gi-map